We are live on ! Find out more
ANTX icon

AN2 Therapeutics
ANTX

52 hedge funds and large institutions have $74.8M invested in AN2 Therapeutics in 2026 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 13 increasing their positions, 8 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

657% more capital invested

Capital invested by funds: $9.88M → $74.8M (+$64.9M)

178% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 9

63% more repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 8

41% more funds holding

Funds holding: 37 → 52 (+15)

29.3% more ownership

Funds ownership: 31.62% → 60.92% (+29%)

Holders
52
Holders Change
+15
Holders Change %
+40.54%
% of All Funds
0.64%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
25
Increased
13
Reduced
8
Closed
9
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
VC
Vivo Capital
California
+$6.51M
2
CC
Commodore Capital
New York
+$4.82M
3
Millennium Management
Millennium Management
New York
+$4.39M
4
SSC
Spruce Street Capital
New York
+$3.43M
5
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$2.06M

Top Sellers

Rank Fund Capital Flow
1
PLC
Peapod Lane Capital
New York
-$1.1M
2
P
Pfizer
New York
-$815K
3
Bank of Montreal
Bank of Montreal
Ontario, Canada
-$334K
4
Renaissance Technologies
Renaissance Technologies
New York
-$289K
5
LCM
Landscape Capital Management
New Jersey
-$276K
Name Holding Trade Value Shares
Change 		Change in
Stake
Citadel Advisors
26
Citadel Advisors
Florida
$531K +$81.9K +39,703 +34%
VFT
27
Vanguard Fiduciary Trust
Pennsylvania
$471K +$284K +137,708 New
State Street
28
State Street
Massachusetts
$394K +$58.2K +28,200 +32%
CC
29
Centiva Capital
New York
$257K +$155K +75,000 New
UBS Group
30
UBS Group
Switzerland
$210K +$9.75K +4,724 +8%
PLC
31
Peapod Lane Capital
New York
$207K -$1.1M -533,542 -90%
BCM
32
Bridgeway Capital Management
Texas
$205K – – –
Northern Trust
33
Northern Trust
Illinois
$148K – – –
CAPTRUST Financial Advisors
34
CAPTRUST Financial Advisors
North Carolina
$137K – – –
PAP
35
Persistent Asset Partners
Hong Kong
$130K +$78.7K +38,155 New
Hudson Bay Capital Management
36
Hudson Bay Capital Management
Connecticut
$118K +$71.4K +34,605 New
HF
37
HRT Financial
New York
$112K +$67.9K +32,924 New
BNP Paribas Financial Markets
38
BNP Paribas Financial Markets
France
$103K +$61.5K +29,775 +9,827%
Qube Research & Technologies (QRT)
39
Qube Research & Technologies (QRT)
United Kingdom
$82.7K +$28.9K +13,984 +137%
XT
40
XTX Topco
Cayman Islands
$76.6K +$46.2K +22,402 New
Citigroup
41
Citigroup
New York
$65.3K +$39.4K +19,088 New
Marshall Wace
42
Marshall Wace
United Kingdom
$60.5K +$36.5K +17,700 New
OAC
43
OMERS Administration Corp
Ontario, Canada
$54K +$32.6K +15,800 New
ACM
44
ADAR1 Capital Management
Texas
$47.4K +$28.6K +13,861 New
PAG
45
Private Advisor Group
New Jersey
$42.8K -$20.6K -10,000 -44%
Federated Hermes
46
Federated Hermes
Pennsylvania
$28.5K -$6.51K -3,157 -28%
VGA
47
Vanguard Global Advisers
Pennsylvania
$25.1K +$15.1K +7,334 New
CIAM
48
Caitong International Asset Management
Hong Kong
$8.89K +$5.37K +2,600 New
TRCT
49
Tower Research Capital (TRC)
New York
$1.96K -$3.03K -1,466 -72%
Barclays
50
Barclays
United Kingdom
$1.37K +$826 +400 New
1
2
3

ANTX Hedge Fund Activity: Q1 2026 in Review

52 of the 8,130 institutional investors tracked by Wall St. Rank reported a position in AN2 Therapeutics (ANTX) for Q1 2026, worth a combined $74.8M — up 657% from $9.88M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new ANTX positions and 9 closed out — a net gain of 16 holders — while 13 added to existing stakes and 8 trimmed.

The largest buyer was Vivo Capital, opening a new position worth an estimated $6.51M. The largest seller was Peapod Lane Capital, cutting an estimated $1.1M.

  • 52 institutional investors held AN2 Therapeutics (ANTX) as of Q1 2026, up from 37 in Q4 2025.
  • Funds reported $74.8M of AN2 Therapeutics stock for Q1 2026, up 657% quarter-over-quarter.
  • 25 funds opened new AN2 Therapeutics positions in Q1 2026 and 9 closed out, a net change of +16 holders.
  • The largest AN2 Therapeutics buyer in Q1 2026 was Vivo Capital, an estimated $6.51M added.
  • The largest AN2 Therapeutics seller in Q1 2026 was Peapod Lane Capital, an estimated $1.1M sold.

Based on aggregated 13F filings for Q1 2026.